335 related articles for article (PubMed ID: 35856894)
1. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
Mo H; Magaki S; Deisch JK; Raghavan R
J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
[TBL] [Abstract][Full Text] [Related]
2. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
4. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
[TBL] [Abstract][Full Text] [Related]
5. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
Christensen BC; Smith AA; Zheng S; Koestler DC; Houseman EA; Marsit CJ; Wiemels JL; Nelson HH; Karagas MR; Wrensch MR; Kelsey KT; Wiencke JK
J Natl Cancer Inst; 2011 Jan; 103(2):143-53. PubMed ID: 21163902
[TBL] [Abstract][Full Text] [Related]
7. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
8. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
Unruh D; Zewde M; Buss A; Drumm MR; Tran AN; Scholtens DM; Horbinski C
Sci Rep; 2019 Jun; 9(1):8946. PubMed ID: 31222125
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
10. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors.
Perycz M; Dabrowski MJ; Jardanowska-Kotuniak M; Roura AJ; Gielniewski B; Stepniak K; Dramiński M; Ciechomska IA; Kaminska B; Wojtas B
Acta Neuropathol Commun; 2024 May; 12(1):72. PubMed ID: 38711090
[TBL] [Abstract][Full Text] [Related]
12. Stalled oligodendrocyte differentiation in IDH-mutant gliomas.
Wei Y; Li G; Feng J; Wu F; Zhao Z; Bao Z; Zhang W; Su X; Li J; Qi X; Duan Z; Zhang Y; Vega SF; Jakola AS; Sun Y; Carén H; Jiang T; Fan X
Genome Med; 2023 Apr; 15(1):24. PubMed ID: 37055795
[TBL] [Abstract][Full Text] [Related]
13. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
14. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
[TBL] [Abstract][Full Text] [Related]
15. Lactate dehydrogenase A silencing in IDH mutant gliomas.
Chesnelong C; Chaumeil MM; Blough MD; Al-Najjar M; Stechishin OD; Chan JA; Pieper RO; Ronen SM; Weiss S; Luchman HA; Cairncross JG
Neuro Oncol; 2014 May; 16(5):686-95. PubMed ID: 24366912
[TBL] [Abstract][Full Text] [Related]
16. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
17. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.
Huang GH; Du L; Li N; Zhang Y; Xiang Y; Tang JH; Xia S; Zhang EE; Lv SQ
Cancer Lett; 2018 Sep; 432():93-102. PubMed ID: 29885519
[TBL] [Abstract][Full Text] [Related]
18. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
[TBL] [Abstract][Full Text] [Related]
20. Region-specific DNA hydroxymethylation along the malignant progression of IDH-mutant gliomas.
Hana T; Mukasa A; Nomura M; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Nejo T; Kitagawa Y; Yamazawa E; Takahashi S; Koike T; Kushihara Y; Takami H; Takayanagi S; Aburatani H; Saito N
Cancer Sci; 2024 May; 115(5):1706-1717. PubMed ID: 38433527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
